Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2318]

Using CT imaging to find radiomic signatures in surgically resected NSCLC

Giulia Mazzaschi - University Hospital Parma, Parma, Italy

Using CT imaging to find radiomic signatures in surgically resected NSCLC ( Giulia Mazzaschi - University Hospital Parma, Parma, Italy )

The role of afatinib in patients with EGFR NSCLC

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

The role of afatinib in patients with EGFR NSCLC ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory...

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

$ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )$

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination...

Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model ( Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas )

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET...

Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1...

Dr James Gulley - National Cancer Institute, Bethesda, USA

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )

Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone...

Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA

$Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )$

TATTON: Updated results for patients with EGFR-mutant NSCLC

Prof Leica Sequist - Massachusetts General Hospital, Boston, USA

TATTON: Updated results for patients with EGFR-mutant NSCLC ( Prof Leica Sequist - Massachusetts General Hospital, Boston, USA )

Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients...

Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )

HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity...

Prof Shoba Navai - Baylor College of Medicine, Houston, USA

HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )

Umbralisib shows early promise for patients with marginal zone lymphoma

Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA

Umbralisib shows early promise for patients with marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )

KEYNOTE trials show pembrolizumab benefited patients with advanced small cell...

Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea

KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )

More from ecancer